Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with
surgical resection of the primary tumour and systemic chemotherapy, which provides …

Pancreatic cancer is one of the leading causes for cancer-related deaths in the United
States. Majority of patients present with unresectable or metastatic disease. For those that …

Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients, yet harbours
mutation-derived T cell neoantigens that are suitable for vaccines,. Here in a phase I trial of …

Background Patients with borderline resectable pancreatic ductal adenocarcinoma have
relatively low resection rates and poor survival despite the use of adjuvant chemotherapy …

The opportunity to detect pancreatic cancer (PC) when potentially curable depends on early
diagnosis and an ability to identify and screen high-risk populations before symptoms arise …

Importance Early results at 3 years from the PRODIGE 24/Canadian Cancer Trials Group
PA6 randomized clinical trial showed survival benefits with adjuvant treatment with modified …

Despite tremendous gains in the molecular understanding of exocrine pancreatic cancer,
the prognosis for this disease remains very poor, largely because of delayed disease …

Survival data for pancreatic cancer are usually based on actuarial calculations and actual
long-term survival rates are rarely reported. Here we use population-level data from the …

Pancreatic cancer is likely to become the second most frequent cause of cancer-associated
mortality within the next decade. Surgical resection with adjuvant systemic chemotherapy …

Background Among patients with metastatic pancreatic cancer, combination chemotherapy
with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer …